JP2024526835A5 - - Google Patents
Info
- Publication number
- JP2024526835A5 JP2024526835A5 JP2024503351A JP2024503351A JP2024526835A5 JP 2024526835 A5 JP2024526835 A5 JP 2024526835A5 JP 2024503351 A JP2024503351 A JP 2024503351A JP 2024503351 A JP2024503351 A JP 2024503351A JP 2024526835 A5 JP2024526835 A5 JP 2024526835A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- polypeptide
- antigen
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163223786P | 2021-07-20 | 2021-07-20 | |
| US63/223,786 | 2021-07-20 | ||
| US202163288111P | 2021-12-10 | 2021-12-10 | |
| US63/288,111 | 2021-12-10 | ||
| PCT/US2022/073877 WO2023004304A1 (en) | 2021-07-20 | 2022-07-19 | Cd8-binding polypeptides and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024526835A JP2024526835A (ja) | 2024-07-19 |
| JP2024526835A5 true JP2024526835A5 (enExample) | 2025-07-18 |
Family
ID=82898944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503351A Pending JP2024526835A (ja) | 2021-07-20 | 2022-07-19 | Ｃｄ８結合ポリペプチド及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250320295A1 (enExample) |
| EP (1) | EP4373854A1 (enExample) |
| JP (1) | JP2024526835A (enExample) |
| CA (1) | CA3225092A1 (enExample) |
| TW (1) | TW202321283A (enExample) |
| WO (1) | WO2023004304A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2541651C (en) | 2003-10-22 | 2011-05-24 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| SG11202106700WA (en) * | 2019-01-07 | 2021-07-29 | Inhibrx Inc | Polypeptides comprising modified il-2 polypeptides and uses thereof |
| EP3980051A4 (en) * | 2019-06-05 | 2023-09-13 | Asher Biotherapeutics, Inc. | FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS |
| JP2022538139A (ja) * | 2019-07-02 | 2022-08-31 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 変異体インターロイキン－２及び抗ｃｄ８抗体を含む免疫複合体 |
| TWI873176B (zh) * | 2019-09-04 | 2025-02-21 | 美商建南德克公司 | Ｃｄ８結合劑及其用途 |
-
2022
- 2022-07-19 EP EP22754735.3A patent/EP4373854A1/en active Pending
- 2022-07-19 US US18/578,133 patent/US20250320295A1/en active Pending
- 2022-07-19 TW TW111127060A patent/TW202321283A/zh unknown
- 2022-07-19 WO PCT/US2022/073877 patent/WO2023004304A1/en not_active Ceased
- 2022-07-19 CA CA3225092A patent/CA3225092A1/en active Pending
- 2022-07-19 JP JP2024503351A patent/JP2024526835A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023513003A5 (enExample) | ||
| JP2024526835A5 (enExample) | ||
| JP2020536549A5 (enExample) | ||
| JP2021520812A5 (enExample) | ||
| JP2020516287A5 (enExample) | ||
| JP2024534838A5 (enExample) | ||
| JP2025504363A5 (enExample) | ||
| Blanco et al. | Bispecific immunomodulatory antibodies for cancer immunotherapy | |
| Nie et al. | Biology drives the discovery of bispecific antibodies as innovative therapeutics | |
| JP2021534783A5 (enExample) | ||
| JP2022116230A5 (enExample) | ||
| TWI828625B (zh) | 引導及導航控制蛋白質以及彼之製造及使用方法 | |
| JP2025078629A5 (enExample) | ||
| JP2019513347A5 (enExample) | ||
| JP2021518142A5 (enExample) | ||
| JP2022516557A5 (enExample) | ||
| IL312224A (en) | Guidance and navigation control proteins and a method for their production and use | |
| IL295878A (en) | Methods for producing cells expressing a chimeric antigen receptor | |
| JP2013515509A5 (enExample) | ||
| JP2017513818A5 (enExample) | ||
| CN108250302A (zh) | 一种多功能蛋白质 | |
| JP2023534847A5 (enExample) | ||
| JP2025508316A5 (enExample) | ||
| JP2024534471A5 (enExample) | ||
| CN115698088A (zh) | 免疫细胞衔接器多特异性结合蛋白及其制备和应用 |